Medtronic acquires Stimgenics to boost chronic pain treatment portfolio

Medtronic has acquired Stimgenics, a Bloomington, Ill.-based company that developed a spinal cord waveform technology designed to treat chronic pain patients, Medtronic announced this week.

Stimgenics developed a spinal cord stimulation waveform called differential multiplexed spinal cord stimulation. Marshall Stanton, MD, president of Medtronic's pain therapies business, said the technology will help create a new treatment option for chronic pain patients. 

The technology will be delivered through Medtronic's Intellis platform, which is an implantable neurostimulator device. 

"I’m thrilled that Medtronic has acquired a therapy that has the potential to significantly improve outcomes for chronic pain patients," said Ricardo Vallejo, MD, PhD, Sterigenics founder. 

The financial terms of the acquisition weren't released, but Medtronic said in a news release that the deal is expected to have a neutral effect on its finances in 2020. 

Read the full news release here

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.